Lupus Nephritis (LN) and focal segmental glomerulosclerosis (FSGS) are chronic kidney diseases with limited treatment options and the potential to progress to end-stage kidney disease. 

Currently treatments focus on broad immunosuppressive therapies, offering limited efficacy and substantial safety and tolerability risk. In refractory cases, dialysis and/or transplantation can become necessary.

ONT01 mitigates inflammation in kidney disease by a multimodal mechanism to target drivers of inflammation systemically (innate immune system) and locally (kidney).